Stonebrook Private Inc. Purchases 276 Shares of Bristol-Myers Squibb (NYSE:BMY)

Stonebrook Private Inc. boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,146 shares of the biopharmaceutical company’s stock after acquiring an additional 276 shares during the quarter. Stonebrook Private Inc.’s holdings in Bristol-Myers Squibb were worth $857,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in BMY. Burney Co. increased its stake in Bristol-Myers Squibb by 4.2% in the fourth quarter. Burney Co. now owns 12,753 shares of the biopharmaceutical company’s stock valued at $721,000 after acquiring an additional 516 shares during the last quarter. Carnegie Investment Counsel grew its stake in shares of Bristol-Myers Squibb by 3.7% during the fourth quarter. Carnegie Investment Counsel now owns 33,435 shares of the biopharmaceutical company’s stock worth $1,891,000 after buying an additional 1,193 shares during the last quarter. Ritholtz Wealth Management grew its stake in shares of Bristol-Myers Squibb by 65.2% during the fourth quarter. Ritholtz Wealth Management now owns 39,389 shares of the biopharmaceutical company’s stock worth $2,228,000 after buying an additional 15,546 shares during the last quarter. Goldstone Financial Group LLC grew its stake in shares of Bristol-Myers Squibb by 6.1% during the fourth quarter. Goldstone Financial Group LLC now owns 4,824 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 279 shares during the last quarter. Finally, Procyon Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 8.3% during the fourth quarter. Procyon Advisors LLC now owns 18,660 shares of the biopharmaceutical company’s stock worth $1,055,000 after buying an additional 1,423 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of the firm’s stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY stock opened at $46.77 on Friday. The firm has a market cap of $95.18 billion, a price-to-earnings ratio of -10.58, a PEG ratio of 2.07 and a beta of 0.39. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company’s fifty day simple moving average is $53.05 and its 200 day simple moving average is $55.99.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($4.40) earnings per share. On average, analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.30%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 92.88%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BMY shares. Citigroup boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Piper Sandler started coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 target price on the stock. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday, February 7th. Finally, Jefferies Financial Group cut their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a report on Wednesday, April 23rd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.